Clinical observation on antiviral efficacy and blocking of mother-to-infant transmission by telbivudine in women with chronic hepatitis B throughout pregnancy
10.3969/j.issn.1006-5725.2016.04.041
- VernacularTitle:慢性乙型肝炎患者妊娠全程替比夫定治疗的疗效及母婴阻断的有效性
- Author:
Fang CHEN
;
Xianglin TU
;
Chuanying CHEN
;
Quanhong CHENG
;
Xin LI
;
Xue LIN
;
Zebin XING
- Publication Type:Journal Article
- Keywords:
Hepatitis B,chronic;
Pregnancy;
Telbivudine;
Therapy
- From:
The Journal of Practical Medicine
2016;32(4):636-639
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore antiviral efficacy, safety and blocking of mother-to-infant transmission by administrating telbivudine in pregnant patients with chronic hepatitis B (CHB) throughout pregnancy. Methods Sixty-four cases of female patients were enrolled. The study participants were divided into the telbivudine treatment group (n = 31) and the control group (n = 33). Data were recorded from beginning of administration to ending pregnancy, as well as notation of any adverse reactions. The neonates and infants were evaluated in HBV infection, parameters of growth and development. Results The recovery rates of ALT, respectively, were 90.32% vs. 57.58% (P = 0.003), 93.55% vs. 62.50% (P = 0.003) at 24 weeks and ante partum and the HBVDNA-negative conversion rates, respectively, were 48.39% vs. 3.03% (P = 0.000), 83.87%vs. 6.06% (P = 0.000), 90.32% vs. 6.25% (P = 0.000) respectively, at 12, 24 weeks of pregnancy and at ante partum between the treatment and control groups. The HBsAg-positive and HBVDNA-positive rates of the infants, respectively, were 12.90% vs. 37.50% (P = 0.025) and 0 vs. 21.88% (P = 0.018) at birth, and respectively, were all 0 vs. 18.75% (P = 0.035) and 0 vs. 18.75% (P = 0.035) at 1, 6, 12 months old between the treatment and control groups. The treatment group showed lower incidence of intrauterine HBV infection (0 vs. 18.75%, P = 0.035). The gestational ages, fetal weights and Apgar scores were not significant different in the children born in the mothers from the two groups. Conclusions Telbivudine administration showed a good antiviral curative effect and effectively blocked mother-to-infant transmission in women with CHB. The treatment was safe and caused no obvious adverse reaction.
